The Pierre Fabre group announced yesterday the introduction of a new governance following the death of its founder on the 20th of July.

Pierre-Yves Revol has been appointed Chairman of Pierre Fabre Participations, the majority shareholder in Pierre Fabre SA. This entity is responsible for approving and ensuring that the Group’s strategy is implemented, as well as choosing the board members and the leaders of Pierre Fabre SA and its direct subsidiaries. Pierre-Yves Revol previously was previously vice-president of Pierre Fabre Participations, as well as of the Board of Pierre Fabre SA, and remains at this position.

© Groupe Pierre Fabre

Furthermore, Pierre Fabre Participations appointed the following persons:

 Jean-Jacques Bertrand, Board member of Pierre Fabre SA was appointed as Chairman of the Pierre Fabre SA Board of Directors. Jean-Jacques Bertrand is 74 years old. He has been a Board member of Pierre Fabre SA since 2010 and is also the Chairman of the Board of Directors of the Guerbet Laboratories, experts in medical imaging.

 Bertrand Parmentier was appointed as CEO of Pierre Fabre SA and a new Board member of this Company. Bertrand Parmentier is 58 years old. He worked with the Pierre Fabre Laboratories for 18 years between 1991 and 2008, as Finance Director, then as Deputy CEO. Since then, he has been with the Latécoère aircraft company, where he is CEO and Chairman of the Board. His return at Pierre Fabre is quite a surprise. “The choice of Bertrand Parmentier as CEO was made after the Group and Didier Miraton had observed that it was not possible, following the death of Pierre Fabre, to come to an agreement on the practicalities of a new governance,” the group commented.

 Jean-Luc Bélingard was appointed as a Board member of Pierre Fabre SA.

 Eric Ducournau was appointed as the President of Pierre Fabre Dermo-Cosmétique (Dermo-cosmetics) SAS, in addition to his role as CEO of this branch.

 Frédéric Duchesne was confirmed as the President of Pierre Fabre Médicament (Pharmaceuticals) SAS, in addition to his role as CEO of this branch.

Eventually, the Pierre Fabre Foundation will meet soon to elect its Chairman. It owns the majority of shares in Pierre Fabre Participations and its priority is to support the access to healthcare in less well-off countries. It does not play a direct role in defining the Group’s strategy or management, which are devolved to Pierre Fabre Participations and Pierre Fabre SA.